Science 37, Inc.

Industry has been quick to embrace decentralized trials as a lasting change, de-risked by the pandemic, and are reporting positive effects and cost savings. But during a recent panel at the Galien Fou

Pyxis Oncology , Theseus Pharmaceuticals, Inc. and Cognition Therapeutics, Inc. launched initial public offerings in the US between 6 and 8 October, raising $373.2m combined, but the first three c

Decentralized clinical trials have been touted for their greater convenience, for enabling clinical investigations during the COVID-19 pandemic and for their ability to increase clinical trial diversi

The market for initial public offerings by biopharmaceutical companies in the US slowed considerably in May after the fast-paced first four months of 2021, which is not surprising given the fact that